% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Schneider:137747,
      author       = {Schneider, F. and Baldauf, K. and Wetzel, W. and Reymann,
                      Klaus},
      title        = {{E}ffects of methylphenidate on the behavior of male
                      5x{FAD} mice.},
      journal      = {Pharmacology, biochemistry and behavior},
      volume       = {128},
      issn         = {0091-3057},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier Science},
      reportid     = {DZNE-2020-04069},
      pages        = {68-77},
      year         = {2015},
      abstract     = {Alzheimer's disease is a neurodegenerative disorder
                      characterized by a loss of memory and spatial orientation.
                      It is also reported that the dopamine system is affected.
                      Dopamine plays a prominent role in motor functions,
                      motivation, emotion, arousal and reward, and it is important
                      for learning and memory. One model that represents
                      characteristic hallmarks of Alzheimer's disease is the 5xFAD
                      mouse model, in which parenchymal plaque load starts at
                      2months of age. Transgenic 5xFAD mice show the first
                      behavioral deficits at 6months, which are evident at 9months
                      of age. In this study, we investigated the pharmacological
                      influence of methylphenidate (MPH) on behavioral deficits of
                      5xFAD mice. Using a battery of behavioral tests, we observed
                      no influence of MPH on anxiety in the elevated plus maze,
                      whereas the locomotion and explorative activity in the open
                      field was increased in transgenic and non-transgenic 5xFAD
                      mice after the application of MPH. Further MPH inhibits
                      habituation in the open field in healthy 5xFAD littermates
                      after the application of 10mg/kg MPH. On the other hand,
                      10mg/kg MPH improved spatial memory in 6-month-old
                      transgenic 5xFAD males, i.e., at a time point when deficits
                      start to occur. However, in 9-month-old transgenic mice, MPH
                      did not improve persisting learning and memory deficits. We
                      concluded that MPH might improve the non-cognitive,
                      apathy-like behavior (indicated by a reduced exploration),
                      but it has no influence on sustained Alzheimer typical
                      learning and memory deficits.},
      keywords     = {Alzheimer Disease: drug therapy / Alzheimer Disease:
                      genetics / Alzheimer Disease: psychology / Amyloid
                      beta-Protein Precursor: genetics / Animals / Anxiety: drug
                      therapy / Behavior, Animal: drug effects / Behavior, Animal:
                      physiology / Central Nervous System Stimulants: pharmacology
                      / Disease Models, Animal / Exploratory Behavior: drug
                      effects / Habituation, Psychophysiologic: drug effects /
                      Humans / Male / Maze Learning: drug effects /
                      Methylphenidate: pharmacology / Mice / Mice, Transgenic /
                      Motor Activity: drug effects / Mutant Proteins: genetics /
                      Presenilin-1: genetics / Amyloid beta-Protein Precursor (NLM
                      Chemicals) / Central Nervous System Stimulants (NLM
                      Chemicals) / Mutant Proteins (NLM Chemicals) / PSEN1
                      protein, human (NLM Chemicals) / Presenilin-1 (NLM
                      Chemicals) / Methylphenidate (NLM Chemicals)},
      cin          = {AG Reymann / Core MR PET},
      ddc          = {540},
      cid          = {I:(DE-2719)1310005 / I:(DE-2719)1340016},
      pnm          = {344 - Clinical and Health Care Research (POF3-344)},
      pid          = {G:(DE-HGF)POF3-344},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:25449360},
      doi          = {10.1016/j.pbb.2014.11.006},
      url          = {https://pub.dzne.de/record/137747},
}